NASDAQ:BIAF bioAffinity Technologies (BIAF) Stock Price, News & Analysis $1.32 -0.06 (-4.35%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.31▼$1.3750-Day Range$1.32▼$2.8252-Week Range$0.95▼$3.62Volume47,899 shsAverage Volume140,752 shsMarket Capitalization$15.39 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get bioAffinity Technologies alerts: Email Address bioAffinity Technologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside354.5% Upside$6.00 Price TargetShort InterestHealthy4.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.73 out of 5 starsMedical Sector564th out of 909 stocksCommercial Physical Research Industry7th out of 11 stocks 3.5 Analyst's Opinion Consensus RatingbioAffinity Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragebioAffinity Technologies has only been the subject of 1 research reports in the past 90 days.Read more about bioAffinity Technologies' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.49% of the float of bioAffinity Technologies has been sold short.Short Interest Ratio / Days to CoverbioAffinity Technologies has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bioAffinity Technologies has recently decreased by 58.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldbioAffinity Technologies does not currently pay a dividend.Dividend GrowthbioAffinity Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIAF. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for bioAffinity Technologies this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for BIAF on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.Percentage Held by Insiders36.44% of the stock of bioAffinity Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.64% of the stock of bioAffinity Technologies is held by institutions.Read more about bioAffinity Technologies' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of bioAffinity Technologies is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bioAffinity Technologies is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiobioAffinity Technologies has a P/B Ratio of 5.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about bioAffinity Technologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About bioAffinity Technologies Stock (NASDAQ:BIAF)bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.Read More BIAF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIAF Stock News HeadlinesSeptember 7 at 1:45 AM | americanbankingnews.comAnalyzing DNAPrint Genomics (OTCMKTS:DNAG) & bioAffinity Technologies (NASDAQ:BIAF)August 5, 2024 | prnewswire.comWallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 MillionSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 2, 2024 | prnewswire.comWallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 MillionJuly 24, 2024 | msn.comMaxim Group Initiates Coverage of bioAffinity Technologies (BIAF) with Buy RecommendationJune 12, 2024 | businesswire.combioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung TestsMay 15, 2024 | msn.comBIAF Stock Earnings: bioAffinity Technologies Reported Results for Q1 2024May 15, 2024 | businesswire.combioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory VolumesSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...May 2, 2024 | businesswire.combioAffinity Technologies News UpdateApril 26, 2024 | investing.combioAffinity Technologies appoints VP to enhance diagnosticsApril 24, 2024 | businesswire.combioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of GrowthApril 9, 2024 | finance.yahoo.combioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer ScreeningApril 9, 2024 | businesswire.combioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer ScreeningMarch 8, 2024 | finance.yahoo.combioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private PlacementMarch 8, 2024 | finance.yahoo.comWallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private PlacementMarch 6, 2024 | msn.comNasdaq Gains 100 Points; Campbell Soup Earnings Top ViewsMarch 6, 2024 | marketwatch.comBioAffinity Technologies Shares Plummet After Stock SaleSee More Headlines Receive BIAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/06/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:BIAF CUSIPN/A CIK1712762 Webwww.bioaffinitytech.com Phone210-698-5334FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+354.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,940,000.00 Net Margins-120.76% Pretax Margin-119.22% Return on Equity-172.06% Return on Assets-106.72% Debt Debt-to-Equity Ratio0.19 Current Ratio1.15 Quick Ratio1.14 Sales & Book Value Annual Sales$7.32 million Price / Sales2.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book5.28Miscellaneous Outstanding Shares11,658,000Free Float7,410,000Market Cap$15.39 million OptionableNot Optionable Beta2.95 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Steven Girgenti (Age 78)Founder & Executive Chairman of the Board Comp: $113.75kMs. Maria Zannes J.D. (Age 68)Founder, President, CEO & Director Comp: $299.17kMs. Julie Anne OvertonDirector of CommunicationsMr. Dallas J. ColemanNational Director of SalesDr. William Bauta Ph.D.Senior Vice President of TherapeuticsKey CompetitorsHeritage GlobalNASDAQ:HGBLJuneeNASDAQ:JUNESPAR GroupNASDAQ:SGRPVivakorNASDAQ:VIVKHaoxi Health TechnologyNASDAQ:HAOView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 14,533 shares on 8/9/2024Ownership: 0.197%Ground Swell Capital LLCBought 22,864 shares on 8/8/2024Ownership: 0.196%View All Institutional Transactions BIAF Stock Analysis - Frequently Asked Questions How have BIAF shares performed this year? bioAffinity Technologies' stock was trading at $1.4705 on January 1st, 2024. Since then, BIAF shares have decreased by 10.2% and is now trading at $1.32. View the best growth stocks for 2024 here. When did bioAffinity Technologies IPO? bioAffinity Technologies (BIAF) raised $8 million in an initial public offering (IPO) on Thursday, September 1st 2022. The company issued 1,300,000 shares at $6.00-$6.25 per share. WallachBeth Capital served as the underwriter for the IPO and Craft Capital Management was co-manager. Who are bioAffinity Technologies' major shareholders? Top institutional investors of bioAffinity Technologies include Renaissance Technologies LLC (0.20%) and Ground Swell Capital LLC (0.20%). How do I buy shares of bioAffinity Technologies? Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIAF) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredThese 2 simple sentences turn every Friday into payday?Most people have never heard of Jim Fink. Behind his humble demeanor and insistence on personal privacy... ...Investing Daily | SponsoredHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees n...Unstoppable Prosperity | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bioAffinity Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
